05.11.2018, 4195 Zeichen

Marinomed: Vienna-based Marinomed Biotech AG, a biopharmaceutical company creating therapies for allergy, respiratory and eye diseases, announced its intention to raise new funds through an Initial Public Offering of new shares with listing of all shares to trading on the official market (Amtlicher Handel) in the prime market segment of the Vienna Stock Exchange. The Offering is subject to market conditions and the approval of the prospectus by the Austrian Financial Market Authority (FMA). The price range for the new shares as well as other details of the Offering will be published in the prospectus before commencement of the offer period of the Offering. The Offering is expected to consist of a public offering to retail and institutional investors in Austria, a private placement outside Austria to selected institutional investors, including a private placement within the United States to qualified institutional buyers in reliance on Rule 144A under the US Securities Act of 1933, as amended, and a private placement outside of the United States to certain other eligible institutional investors in reliance on Regulation S under the US Securities Act of 1933, as amended. The Offering will consist exclusively of new bearer shares of Marinomed. The planned listing on the Vienna Stock Exchange is intended to allow Marinomed to continue its success story using the strategic and financial flexibility available to a listed stock company. Erste Group and Kempen are acting as Joint Global Coordinators and Joint Bookrunners. 

RHI Magnesita: RHI Magnesita N.V., a leading supplier of refractory products, announced a trading update for the three months to September 2018. The company said it has seen a good trading performance in the third quarter, which continues to reflect the positive trends seen in the first half of 2018, driven by solid end-markets, the positive response by customers to the Group’s full portfolio and solution offering, stable raw material pricing and the delivery of the merger synergies. In this stable environment the Group has further improved its EBITDA margin profile in Q3. RHI Magnesita continues to make progress in the strategic markets of India and China and continues to observe the effects from the imposition of trade tariffs. To date the Group has been cushioned from any significant impact from these developments by its diversified production base and client base. The Group continues to successfully achieve its integration plans and remains on track to achieve the recently increased synergy targets of at least Euro 60 mn in 2018 and Euro 110 mn by 2020. RHI Magnesita regularly seeks to evaluate opportunities that may arise to participate in the ongoing consolidation of the refractory industry in many of the global markets. As announced previously, the Company continues to consider a potential transaction involving Kumas Manyezit Sanayi AS and will update the market as appropriate in due course. The strong trading performance reported to date in 2018 continues, supported by solid demand from the Group’s end markets, the benefits of raw material integration and the realisation of synergies. Therefore, save for the PPA-related adjustments, management expectations for full year 2018 operating results remain unchanged.
RHI Magnesita: weekly performance: -6.32%

OMV: In the course of a working meeting, Alexey Miller, Chairman of the Gazprom Management Committee, and Rainer Seele, Chairman of the Executive Board of OMV signed an Amendment to the contract on gas supplies to Austria. According to the document, gas deliveries to Austria will be increased by 1 billion cubic meters per year beyond the contractual amount for the entire contract period. "Europe's demand for gas will rise primarily as the result of gas-fired power plants successively replacing coal, coupled with the simultaneous decrease in European production. By increasing gas supplies to Baumgarten in Lower Austria, we are making an additional contribution to security of supply in Austria – as well as to other European countries,” said Rainer Seele.
OMV: weekly performance: -0.37%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (05/11/2018)

Christian Drastil: Wiener Börse Plausch

Wiener Börse Party #637: Egalite Addiko und Marinomed, AT&S nach 2 Monaten zurück, 19 Jahre RBI an der Börse, Strabag top

Bildnachweis

Aktien auf dem Radar:Addiko Bank, Immofinanz, Marinomed Biotech, Flughafen Wien, Warimpex, EuroTeleSites AG, ATX Prime, ams-Osram, AT&S, Palfinger, RBI, Strabag, Pierer Mobility, UBM, CA Immo, Frequentis, Lenzing, SW Umwelttechnik, Oberbank AG Stamm, Wolford, Agrana, Amag, Erste Group, EVN, Kapsch TrafficCom, OMV, Österreichische Post, Telekom Austria, Uniqa, VIG, Wienerberger.

---